ORLANDO, Fla., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the BIO CEO & Investor Conference on Monday, February 12th at 9:15AM ET (the time may be subject to changes depending on the conference organizers) at the New York Marriott Marquis in New York City. Thomas K. Equels, M.S. J.D., Chief Executive Officer of Hemispherx Biopharma, will be presenting as well as meeting with investors. His presentation will focus on the large size of potential markets for three key development areas: 1) ME/CFS; 2) immuno-oncology; and, 3) immune system amplification for enhanced viral vaccines.

Hemispherx has two flagship products: Alferon N Injection® and the experimental therapeutic Ampligen®. The Company also has six orphan drug designations with four in the U.S. and two in the European Union. The Company has recently outlined the activity of Ampligen® (rintatolimod) in enabling nasally-administered seasonal flu vaccines to confer wide cross-reactivity/protection against influenza viruses, even against those they were not designed to protect.

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. 

A bout Hemispherx Biopharma Hemispherx Biopharma, Inc., is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.

Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

ContactHemispherx Biopharma Phone Number: 800-778-4042 Email: IR@hemispherx.net

Primary Logo